3月 2026
- 首頁
- e-Zyvec's Technology
3月 2026e-Zyvec's Technology的市場佔有率分析
At Polyplus, our innovative plasmid engineering technology e-Zyvec enables assembly of ready-to-use plasmids in a single and controlled reaction from a library of DNA bricks.
e-Zyvec's Technology(包含公司地區)
查看更多網站流量與參與度資訊- polyplus-sartorius.com
e-Zyvec's Technology的熱門網域總造訪量
了解e-Zyvec's Technology市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
e-Zyvec's Technology的熱門網域平均造訪時長
分析e-Zyvec's Technology參與度指標。
過去 3 個月平均造訪時長
子公司細目
e-Zyvec's Technology的熱門網域平均頁面瀏覽量
了解e-Zyvec's Technology如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自e-Zyvec's Technology
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Polyplus Inc launches innovative plasmid for AAV vector production.Polyplus launches innovative plasmid for AAV vector production, strengthening its position in biologic and cell & gene therapy solutions.
3月 26, 2024閱讀更多
新聞Polyplus Inc is developing CGT efficiency standards.Polyplus, part of Sartorius, agreed to collaborate with MarkHerz, a Korean cell and gene therapy (CGT) CDMO, to develop new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product.
12月 18, 2023閱讀更多
新聞Sartorius acquired Polyplus Inc for $2.6B on Apr 1st '23.Further, it is worth highlighting that in April 2023, Sartorius announced the acquisition of Polyplus for total amount of USD 2.6 billion with an aim to strengthen its portfolio for transfection reagents, DNA/RNA delivery reagents for the production of viral vectors.
9月 19, 2023閱讀更多
查看所有e-Zyvec's Technology信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
